Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) grapples with a concerning financial state, showcasing a Return on Invested Capital (ROIC) of -72.78% and a Weighted Average Cost of Capital (WACC) at 15.44%. This combination signals inefficient capital utilization.

In contrast to its peers, like Krystal Biotech, which displays operational efficiency, Rhythm faces notable challenges in generating adequate returns.